Oncolytics Net Interest Income from 2010 to 2026
| ONCY Stock | USD 0.89 0.05 5.95% |
Net Interest Income | First Reported 2019-03-31 | Previous Quarter 104 K | Current Value 100 K | Quarterly Volatility 142.2 K |
Check Oncolytics Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncolytics Biotech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 87.2 K, Interest Expense of 637.6 K or Selling General Administrative of 16.1 M, as well as many indicators such as Price To Sales Ratio of 66.83, Dividend Yield of 0.0 or PTB Ratio of 20.28. Oncolytics financial statements analysis is a perfect complement when working with Oncolytics Biotech Valuation or Volatility modules.
Oncolytics | Net Interest Income | Build AI portfolio with Oncolytics Stock |
The evolution of Net Interest Income for Oncolytics Biotech provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Oncolytics Biotech compares to historical norms and industry peers.
Latest Oncolytics Biotech's Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Oncolytics Biotech over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Oncolytics Biotech's Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncolytics Biotech's overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Oncolytics Net Interest Income Regression Statistics
| Arithmetic Mean | 444,390 | |
| Geometric Mean | 270,592 | |
| Coefficient Of Variation | 112.13 | |
| Mean Deviation | 409,728 | |
| Median | 163,902 | |
| Standard Deviation | 498,306 | |
| Sample Variance | 248.3B | |
| Range | 1.3M | |
| R-Value | 0.77 | |
| Mean Square Error | 106.4B | |
| R-Squared | 0.60 | |
| Significance | 0.0003 | |
| Slope | 76,339 | |
| Total Sum of Squares | 4T |
Oncolytics Net Interest Income History
About Oncolytics Biotech Financial Statements
Oncolytics Biotech investors use historical fundamental indicators, such as Oncolytics Biotech's Net Interest Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncolytics Biotech. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 1.4 M | 1.4 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.